Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.54
+0.5%		$7.08
$4.73
▼
$9.53
$678.23M0.411.05 million shs962,556 shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$29.89
+2.0%		$37.74
$22.10
▼
$45.14
$2.35B0.92.40 million shs992,726 shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$62.06
+2.1%		$73.58
$40.00
▼
$99.50
$2.38B0.93651,186 shs691,133 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$4.36
+10.4%		$3.57
$2.77
▼
$7.18
$2.33B1.0428.49 million shs35.33 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
0.00%+7.39%-6.44%-4.39%+7.39%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
0.00%-5.56%-21.55%-23.57%+9.73%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.00%-3.80%-16.29%-18.97%-11.70%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+5.83%+37.97%+22.47%-28.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.54
+0.5%		$7.08
$4.73
▼
$9.53
$678.23M0.411.05 million shs962,556 shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$29.89
+2.0%		$37.74
$22.10
▼
$45.14
$2.35B0.92.40 million shs992,726 shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$62.06
+2.1%		$73.58
$40.00
▼
$99.50
$2.38B0.93651,186 shs691,133 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$4.36
+10.4%		$3.57
$2.77
▼
$7.18
$2.33B1.0428.49 million shs35.33 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
0.00%+7.39%-6.44%-4.39%+7.39%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
0.00%-5.56%-21.55%-23.57%+9.73%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.00%-3.80%-16.29%-18.97%-11.70%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+5.83%+37.97%+22.47%-28.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
2.33
Hold$17.50167.58% Upside
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.86
Moderate Buy$61.92107.17% Upside
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2.77
Moderate Buy$110.1877.54% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$8.0684.86% Upside

Current Analyst Ratings Breakdown

Latest AURA, RXRX, CLDX, and IRON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$64.00
9/23/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$70.00 ➝ $88.00
9/23/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$50.00 ➝ $57.00
9/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$68.00
9/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$42.00 ➝ $64.00
9/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$61.00 ➝ $72.00
9/16/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$79.00 ➝ $86.00
9/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$128.00
9/10/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$46.00 ➝ $50.00
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$2.16 per shareN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$1.54M1,524.20N/AN/A$7.93 per share3.77
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$19.52 per shareN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M31.25N/AN/A$2.14 per share2.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$106.19M-$1.75N/AN/AN/AN/A-73.18%-62.00%11/12/2026 (Estimated)
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$258.76M-$4.35N/AN/AN/AN/A-52.35%-47.61%11/9/2026 (Estimated)
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$212.18M-$6.58N/AN/AN/AN/A-37.17%-33.65%11/5/2026 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$1.04N/AN/AN/A-945.94%-50.41%-38.25%11/4/2026 (Estimated)

Latest AURA, RXRX, CLDX, and IRON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.63N/AN/AN/A$1.88 millionN/A
11/4/2026Q3 2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.24N/AN/AN/A$12.98 millionN/A
8/11/2026Q2 2026
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.3750-$0.48-$0.1050-$0.48N/AN/A
8/6/2026Q2 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.06-$0.94+$0.12-$0.94$0.74 million$0.02 million
8/5/2026Q2 2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.24-$0.25-$0.01-$0.25$10.97 million$7.67 million
7/30/2026Q2 2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.71-$1.54+$0.17-$1.54$1.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
16.82
16.82
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
11.82
11.82
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.09
24.14
24.14
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.01
5.03
5.03

Institutional Ownership

CompanyInstitutional Ownership
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
1.90%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5.20%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.76%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
113103.71 million101.74 millionNot Optionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
19878.53 million74.45 millionOptionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
16538.39 million36.95 millionNot Optionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
600535.34 million499.74 millionOptionable

Recent News About These Companies

What Could Go Wrong With Recursion Pharmaceuticals Stock?
October 10 at 3:46 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/could-wrong-recursion-pharmaceuticals-stock-235814594.html
Why Recursion Pharmaceuticals, Inc.’s (RXRX) Stock Is Down 10.42%
October 9 at 12:43 PM  |  aaii.comA
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Blake Borgeson Sells 50,000 Shares
October 9 at 4:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31103011
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 25,000 Shares of Stock
October 8 at 6:22 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rxrx-insider-buying-and-selling-2026-10-08/
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $125,000.00 in Stock
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-recursion-pharmaceuticals-nasdaq-rxrx-director-sells-12500000-in-stock-2026-10-07/
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 50,000 Shares of Stock
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-recursion-pharmaceuticals-nasdaq-rxrx-director-sells-50000-shares-of-stock-2026-10-07/
Stock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094235
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
October 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3001380/recursion-pharmaceuticals-rxrx-stock-declines-while-market-improves-some-information-for-investors?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-3001380
Cathie Wood’s ARK Sells Twist Bioscience Shares, Buys Recursion and Intellia
October 6, 2026  |  coincentral.comC
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Falls 4.3% - Here's Why
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-recursion-pharmaceuticals-nasdaq-rxrx-stock-falls-43-heres-why-2026-10-06/
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Sees Heavy Call Option Buying
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-recursion-pharmaceuticals-nasdaq-rxrx-stock-sees-heavy-call-option-buying-2026-10-05/
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10% - Here's Why
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088111
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10% - Should You Buy?
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-recursion-pharmaceuticals-nasdaq-rxrx-stock-price-up-10-should-you-buy-2026-10-05/
Recursion Pharmaceuticals (NASDAQ:RXRX) and Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Comparison
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086315
Most and least shorted mid- to mega-cap healthcare stocks at the end of September
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/most-and-least-shorted-mid-to-mega-cap-healthcare-stocks-at-the-end-of-september/ar-AA2dqMpb
Reviewing Recursion Pharmaceuticals (NASDAQ:RXRX) & Zealand Pharma A/S (OTCMKTS:ZLDPF)
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068477
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Climb 4.7% - What's Next?
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-recursion-pharmaceuticals-nasdaq-rxrx-shares-climb-47-whats-next-2026-09-29/
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
September 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2997059/recursion-pharmaceuticals-rxrx-registers-a-bigger-fall-than-the-market-important-facts-to-note?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-2997059
Recursion Pharmaceuticals Inc (RXRX)
September 25, 2026  |  ru.investing.comhttps://ru.investing.com/equities/recursion-pharmaceuticals-news
Cours Recursion Pharmaceuticals, Inc.
September 25, 2026  |  zonebourse.comZ
Squeeze Watch: 10 Stocks With Over 33% Short Interest
September 25, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/62004722/squeeze-watch-10-stocks-with-over-33-short-interest?utm_source=snapi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
McDonald's fries, a Dutch Bros iced drink, and Wingstop wings displayed against a declining red stock chart background.
3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure Builds
By Dan Schmidt | September 24, 2026
Cracker Barrel logo displayed over a breakfast plate with pancakes, eggs, and bacon inside a restaurant dining room.
Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
By Chris Markoch | September 25, 2026
Exterior of a Texas Roadhouse restaurant at dusk with customers entering and a worker unloading boxes from a delivery truck.
Despite Record Sales, Texas Roadhouse Has Beef With Beef Costs
By Peter Frank | September 22, 2026
Darden Restaurants logo displayed over a table of pasta dishes, salad, and breadsticks in a restaurant setting.
Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
By Thomas Hughes | September 26, 2026
CAVA logo overlaid on a grain bowl with grilled chicken, pita, and hummus in a restaurant setting.
CAVA Stock Slips: Sector Fear or Valuation Reality?
By Chris Markoch | September 27, 2026
Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$6.54 +0.03 (+0.46%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$6.52 -0.01 (-0.23%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$29.89 +0.59 (+2.01%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$30.00 +0.11 (+0.37%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$62.06 +1.29 (+2.12%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$62.13 +0.07 (+0.11%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$4.36 +0.41 (+10.38%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$4.38 +0.02 (+0.57%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas